In 470 adolescents with suppressed HIV in Africa, short-cycle ART (5 days on, 2 off) failed non-inferiority vs continuous ART: estimated confirmed viral rebound by week 96 was 9.9% vs 4.8%, significantly higher with short-cycle ART.
RCTn = 470
Kekitiinwa et al. Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial